



|                                     | Dr. Vinay Cho<br>MD (Pathology & N<br>Chairman & Consu | 1icrobiology)       | Dr. Yugan<br>MD<br>CEO & Consultant | (Pathology)                   |  |  |
|-------------------------------------|--|---------------------|-------------------------------------|-------------------------------|--|--|
| NAME                                | : Mrs. KAMLESH   |                     |                                     |                               |  |  |
| AGE/ GENDER                         | : 52 YRS/FEMALE  | P                   | ATIENT ID                           | : 1808013                     |  |  |
| COLLECTED BY                        |  | R                   | EG. NO./LAB NO.                     | : 012503270010                |  |  |
| REFERRED BY                         | •  |                     | EGISTRATION DATE                    | : 27/Mar/2025 08:16 AM        |  |  |
|                                     |  |                     |                                     |                               |  |  |
| BARCODE NO.                         | : 01527842   |                     | OLLECTION DATE                      | : 27/Mar/2025 08:21AM         |  |  |
| CLIENT CODE.                        | : KOS DIAGNOSTIC LAB                                   | R                   | EPORTING DATE                       | : 27/Mar/2025 01:04PM         |  |  |
| CLIENT ADDRESS                      | : 6349/1, NICHOLSON ROAD, Al                           | MBALA CANTT         |                                     |                               |  |  |
| Test Name                           |  | Value               | Unit                                | Biological Reference interval |  |  |
| WHOLE BLOOD<br>by HPLC (HIGH PERFOR | AEMOGLOBIN (HbA1c):<br>RMANCE LIQUID CHROMATOGRAPHY)   | 6.6 <sup>H</sup>    | EMOGLOBIN (HBA<br>%                 | 4.0 - 6.4                     |  |  |
|                                     | AGE PLASMA GLUCOSE<br>RMANCE LIQUID CHROMATOGRAPHY)    | 142.72 <sup>H</sup> | mg/dL                               | 60.00 - 140.00                |  |  |
|                                     | AS PER AMERICAN D                                      | INBETES ASSOCIAT    |                                     |                               |  |  |
| F                                   | REFERENCE GROUP  |                     | COSYLATED HEMOGLOGIB                | (HBAIC) in %                  |  |  |
|                                     | Non diabetic Adults >= 18 years                        |                     | <5.7                                |                               |  |  |
| At Risk (Prediabetes)               |  |                     | 5.7 - 6.4                           |                               |  |  |
| Di                                  | agnosing Diabetes                                      | >= 6.5              |                                     |                               |  |  |
| Therapeuti                          | c goals for glycemic control                           | Actions S           | Age > 19 Years           Therapy:   | < 7.0<br>>8.0                 |  |  |
| COMMENTS:                           |  | Goal of therapy:    |                                     | <7.5                          |  |  |

**KOS Diagnostic Lab** 

(A Unit of KOS Healthcare)

1.Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients. 2.Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.

3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropriate.

4.High HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications 5.Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia, increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7.Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

 KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana

 KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana

 0171-2643898, +91 99910 43898
 care@koshealthcare.com
 www.koshealthcare.com





TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.



KOS Diagnostic Lab (A Unit of KOS Healthcare)

|   | MD   | Vinay Chopra<br>(Pathology & Microbiol<br>irman & Consultant Pat |                                 | Dr. Yugan<br>MD<br>CEO & Consultant           | (Pathology)  |       |
|---|--|--|---------------------------------|---|--|-------|
| NAME  | : Mrs. KAMLESH                               |  |                                 |   |  |       |
| AGE/ GENDER                                     | : 52 YRS/FEMALE                              |  | PATI                            | ENT ID  | : 1808013  |       |
| COLLECTED BY                                    | :  |  | REG.                            | NO./LAB NO.                                   | : 012503270010   |       |
| REFERRED BY                                     | :  |  | REGI                            | STRATION DATE                                 | : 27/Mar/2025 08:16 AM   |       |
| BARCODE NO.                                     | :01527842                                    |  | COLL                            | ECTION DATE                                   | : 27/Mar/2025 08:21AM  |       |
| CLIENT CODE.                                    | : KOS DIAGNOSTI                              | C LAB  | REPO                            | RTING DATE                                    | : 27/Mar/2025 11:19AM  |       |
| CLIENT ADDRESS                                  | : 6349/1, NICHOL                             | SON ROAD, AMBALA (   | CANTT                           |   |  |       |
| Test Name                                       |  | Val  | ue                              | Unit  | Biological Reference inte  | erval |
|   |  | CLINICAL CH  |                                 |   | STRY   |       |
|   |  | GLU  | COSE FAS                        |   |  |       |
| GLUCOSE FASTIN                                  | G (F): PLASMA<br>E - PEROXIDASE (GOD         | -POD) 129  | 9.8 <sup>H</sup>                | mg/dL   | NORMAL: < 100.0<br>PREDIABETIC: 100.0 - 12<br>DIABETIC: > 0R = 126.0   | 25.0  |
| test (after consumpti<br>3. A fasting plasma gl | on of 75 gms of gluc<br>ucose level of above | e 125 ma/dl is hiahly su   | Jaaestive of d                  | iabetic state. A repe                         | at post-prandial is strongly recommenden<br>natory for diabetic state. |       |
| test (after consumpti<br>3. A fasting plasma gl | on of 75 gms of gluc<br>ucose level of above | e 125 mg/dl is highly su<br>evel in excess of 125 m              | uggestive of d<br>1g/dl on both | iabetic state. A repe<br>occasions is confirm | at post-prandial is strongly recommenden<br>natory for diabetic state. |       |
| 3. A fasting plasma gl                          | on of 75 gms of gluc<br>ucose level of above | e 125 mg/dl is highly su<br>evel in excess of 125 m              | Jaaestive of d                  | iabetic state. A repe<br>occasions is confirm | at post-prandial is strongly recommende<br>atory for diabetic state.   |       |
| test (after consumpti<br>3. A fasting plasma gl | on of 75 gms of gluc<br>ucose level of above | e 125 mg/dl is highly su<br>evel in excess of 125 m              | uggestive of d<br>1g/dl on both | iabetic state. A repe<br>occasions is confirm | at post-prandial is strongly recommenden<br>natory for diabetic state. |       |
| test (after consumpti<br>3. A fasting plasma gl | on of 75 gms of gluc<br>ucose level of above | e 125 mg/dl is highly su<br>evel in excess of 125 m              | uggestive of d<br>1g/dl on both | iabetic state. A repe<br>occasions is confirm | at post-prandial is strongly recommendent                              |       |
| test (after consumpti<br>3. A fasting plasma gl | on of 75 gms of gluc<br>ucose level of above | e 125 mg/dl is highly su<br>evel in excess of 125 m              | uggestive of d<br>1g/dl on both | iabetic state. A repe<br>occasions is confirm | at post-prandial is strongly recommendent                              |       |
| test (after consumpti<br>3. A fasting plasma gl | on of 75 gms of gluc<br>ucose level of above | e 125 mg/dl is highly su<br>evel in excess of 125 m              | uggestive of d<br>1g/dl on both | iabetic state. A repe<br>occasions is confirm | at post-prandial is strongly recommendent                              |       |
| test (after consumpti<br>3. A fasting plasma gl | on of 75 gms of gluc<br>ucose level of above | e 125 mg/dl is highly su<br>evel in excess of 125 m              | uggestive of d<br>1g/dl on both | iabetic state. A repe<br>occasions is confirm | at post-prandial is strongly recommendent                              |       |
| test (after consumpti<br>3. A fasting plasma gl | on of 75 gms of gluc<br>ucose level of above | e 125 mg/dl is highly su<br>evel in excess of 125 m              | uggestive of d<br>1g/dl on both | iabetic state. A repe<br>occasions is confirm | at post-prandial is strongly recommendent                              |       |
| test (after consumpti<br>3. A fasting plasma gl | on of 75 gms of gluc<br>ucose level of above | e 125 mg/dl is highly su<br>evel in excess of 125 m              | uggestive of d<br>1g/dl on both | iabetic state. A repe<br>occasions is confirm | at post-prandial is strongly recommendentatory for diabetic state.     |       |
| test (after consumpti<br>3. A fasting plasma gl | on of 75 gms of gluc<br>ucose level of above | e 125 mg/dl is highly su<br>evel in excess of 125 m              | uggestive of d<br>1g/dl on both | iabetic state. A repe<br>occasions is confirm | at post-prandial is strongly recommendentatory for diabetic state.     |       |
| test (after consumpti<br>3. A fasting plasma gl | on of 75 gms of gluc<br>ucose level of above | e 125 mg/dl is highly su<br>evel in excess of 125 m              | uggestive of d<br>1g/dl on both | iabetic state. A repe<br>occasions is confirm | at post-prandial is strongly recommendentatory for diabetic state.     |       |
| test (after consumpti<br>3. A fasting plasma gl | on of 75 gms of gluc<br>ucose level of above | e 125 mg/dl is highly su<br>evel in excess of 125 m              | uggestive of d<br>1g/dl on both | iabetic state. A repe<br>occasions is confirm | at post-prandial is strongly recommendentatory for diabetic state.     |       |
| test (after consumpti<br>3. A fasting plasma gl | on of 75 gms of gluc<br>ucose level of above | e 125 mg/dl is highly su<br>evel in excess of 125 m              | uggestive of d<br>1g/dl on both | iabetic state. A repe<br>occasions is confirm | at post-prandial is strongly recommendentatory for diabetic state.     |       |
| test (after consumpti<br>3. A fasting plasma gl | on of 75 gms of gluc<br>ucose level of above | e 125 mg/dl is highly su<br>evel in excess of 125 m              | uggestive of d<br>1g/dl on both | iabetic state. A repe<br>occasions is confirm | at post-prandial is strongly recommendentatory for diabetic state.     |       |

